Engineered bacteria launch and control an oncolytic virus

The ability of bacteria and viruses to selectively replicate in tumours has led to synthetic engineering of new microbial therapies. Here we design a cooperative strategy whereby Salmonella typhimurium bacteria transcribe and deliver the Senecavirus A RNA genome inside host cells, launching a potent oncolytic viral infection. 'Encapsidated' by bacteria, the viral genome can further bypass circulating antiviral antibodies to reach the tumour and initiate replication and spread within immune mice. Finally, we engineer the virus to require a bacterially delivered protease to achieve virion maturation, demonstrating bacterial control over the virus. Together, we refer to this platform as 'CAPPSID' for Coordinated Activity of Prokaryote and Picornavirus for Safe Intracellular Delivery. This work extends bacterially delivered therapeutics to viral genomes, and shows how a consortium of microbes can achieve a cooperative aim.

Authors

Institutions

Publication Details

Journal
Nature Biomedical Engineering
Published
2025-08-15
DOI
https://doi.org/10.1038/s41551-025-01476-8
Citations
9
Primary Topic
Cancer Research and Treatments
Type
article
Field-Weighted Citation Impact
11.09

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Engineered bacteria launch and control an oncolytic virus

Hongsheng Luo, Zakary S. Singer, Charles M. Rice, Courtney Coker et al.
9 citations
Nature Biomedical Engineering
Cancer Research and Treatments
11.09
article

Engineered bacteria launch and control an oncolytic virus

Hongsheng Luo, Zakary S. Singer, Charles M. Rice, Courtney Coker, Tal Danino, Jonathan Pabón, Kathleen A. Grant, William Sun, Hsinyen Huang, Ijeoma Obi
article en
9 citations

Abstract

The ability of bacteria and viruses to selectively replicate in tumours has led to synthetic engineering of new microbial therapies. Here we design a cooperative strategy whereby Salmonella typhimurium bacteria transcribe and deliver the Senecavirus A RNA genome inside host cells, launching a potent oncolytic viral infection. 'Encapsidated' by bacteria, the viral genome can further bypass circulating antiviral antibodies to reach the tumour and initiate replication and spread within immune mice. Finally, we engineer the virus to require a bacterially delivered protease to achieve virion maturation, demonstrating bacterial control over the virus. Together, we refer to this platform as 'CAPPSID' for Coordinated Activity of Prokaryote and Picornavirus for Safe Intracellular Delivery. This work extends bacterially delivered therapeutics to viral genomes, and shows how a consortium of microbes can achieve a cooperative aim.

Nature Biomedical EngineeringVol. 10(3)
Columbia University Irving Medical Center (US), Columbia University (US), Rockefeller University (US)
National Institutes of Health
Openalex Percentile: Top 1%
Cancer Research and Treatments
11.09
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Engineered bacteria launch and control an oncolytic virus — Hongsheng Luo, Zakary S. Singer, et al. · Nature Biomedical Engineering (2025) | TGRS Research Map | TGRS